February 19, 2025
Sulfasalazine Market

Increasing adoption as a first line treatment option to drive the growth of Sulfasalazine Market

The global Sulfasalazine Market is estimated to be valued at US$ 2.01 Bn or Mn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Sulfasalazine is an anti-inflammatory drug used mainly in the treatment of ulcerative colitis and rheumatoid arthritis. It contains sulfapyridine linked to 5-aminosalicylic acid via an azo bond. Sulfasalazine suppresses inflammation and works by blocking the transport of prostaglandins. It is available in tablet form and usually prescribed as the first treatment option for ulcerative colitis and rheumatoid arthritis due to its effectiveness and low adverse effect profile as compared to other treatment options.

Market key trends:

One of the key trends in the Sulfasalazine Market Size is its increasing adoption as the first line treatment option for ulcerative colitis and rheumatoid arthritis. As per studies, sulfasalazine is showing better efficacy in inducing remission with minimal side effects when prescribed at initial stages, thus seeing increased preference over other biologic treatment options. Also, the patent expiration of major sulfasalazine brands is expected to fuel the growth of generic versions, thereby augmenting market revenues. Intensifying research to develop novel drug delivery systems and combinational therapies incorporating sulfasalazine will further aid the market during the forecast period.

Porter’s Analysis

Threat of new entrants: New entrants in the sulfasalazine market face high capital requirements for R&D, manufacturing, and marketing. The market also has well established players with strong brands and relationships.
Bargaining power of buyers: Buyers have moderate bargaining power due to availability of generic alternatives. However, patented brands have pricing power.
Bargaining power of suppliers: A few major players control the key raw material supply. However, availability of substitutes balances suppliers’ bargaining power.
Threat of new substitutes: Emergence of new drugs for inflammatory bowel disease and arthritis can threaten sulfasalazine sales. However, its strong efficacy and affordability maintain market potential.
Competitive rivalry: The market has few leading global and regional players. Intense competition on pricing and new product development keeps rivalry high.

Key Takeaways

The global sulfasalazine market is expected to witness high growth, exhibiting CAGR of 5.7% over the forecast period, due to increasing prevalence of autoimmune diseases. The market size for 2023 is US$ 2.01 Bn.
North America dominates the sulfasalazine market aided by developed healthcare infrastructure and high disease awareness. However, Asia Pacific is expected to register fastest growth attributed to rising healthcare spending in China and India.

Key players operating in the sulfasalazine market are Pfizer Inc., Teva Pharmaceuticals, Mylan N.V., Dr. Reddy’s Laboratories, Zydus Cadila, Sun Pharmaceutical Industries, Aspen Pharmacare, Apotex Inc., Sandoz (a division of Novartis), Lupin Limited. These companies collectively account for over 50% of total market share.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it

Money Singh
+ posts

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. 

Money Singh

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. 

View all posts by Money Singh →